QLi5 Therapeutics GmbH announced that it has received €10 million in funding from KHANU Management GmbH, SV Investment Corporation, Atinum Investment Co., Ltd, Daol Investment & Securities Co., Ltd.
September 06, 2022
Share
QLi5 Therapeutics GmbH announced that it has raised €10 million in a round of funding on September 7, 2022. The transaction included participation from Atinum Investment Co., Ltd,Daol Investment & Securities Co., Ltd., returning investors KHAN Technology Transfer Fund I, a fund managed by KHANU Management GmbH and SV Investment Corporation.
Atinum Investment Co., Ltd is a Korea-based company principally engaged in the venture investment business. It mainly invests in information technology (IT) and communication, renewable and energy, bio and life science, materials and components, as well as media and contents industries. The Companyâs principal activities consist of venture support services, including the consulting of foundation procedures, start-up capital support procedures, tax and accounting, and government support policies; support services for its investment companies including business consulting services of technology trends, strategy plans, human resource plans, initial public offerings (IPOs), restructurings, mergers and acquisitions (M&As), market information and others, and international supports services such as overseas corporation investments as well as cooperative mutual investments of domestic and overseas corporations.
QLi5 Therapeutics GmbH announced that it has received €10 million in funding from KHANU Management GmbH, SV Investment Corporation, Atinum Investment Co., Ltd, Daol Investment & Securities Co., Ltd.
ATINUM INVESTMENT CO., LTD 
